<?xml version="1.0" encoding="UTF-8"?>
<p id="par0015">SARS-CoV-2 HKU-001a (GenBank accession number: MT230904​) was isolated from the nasopharyngeal aspirate specimen of a laboratory-confirmed COVID-19 patient in Hong Kong [
 <xref rid="bib0085" ref-type="bibr">17</xref>]. MERS-CoV EMC/2012 strain (GenBank accession number: NC_019843.3) was kindly provided by Ron Rouchier (Erasmus Medical Center, Rotterdam, the Netherlands) [
 <xref rid="bib0090" ref-type="bibr">18</xref>]. The viruses were propagated in VeroE6 cells and kept at −80 °C in aliquots until use. Plaque forming unit (PFU) and TCID
 <sub>50</sub> assays were performed to titrate the cultured SARS-CoV-2. VeroE6 (ATCC® CRL-1586™) and Caco2 cells (ATCC® HTB-37™) were purchased from ATCC and maintained in Dulbecco’s modified eagle medium (DMEM, Gibco, CA, USA) culture medium supplemented with 10 % heat-inactivated fetal bovine serum (FBS, Gibco), 50 U/mL penicillin, and 50 μg/ml streptomycin as previously described [
 <xref rid="bib0085" ref-type="bibr">17</xref>]. All experiments involving live SARS-CoV-2 and MERS-CoV followed the approved standard operating procedures of the Biosafety Level 3 facility at the Department of Microbiology, The University of Hong Kong, as previously described [
 <xref rid="bib0095" ref-type="bibr">19</xref>,
 <xref rid="bib0100" ref-type="bibr">20</xref>]. The FDA-approved drug library (Cat# HY-L022) and all the tested drug compounds were purchased from MedChem Express (Monmouth Junction, NJ, USA).
</p>
